The Alginate patent protects the ability to compose and manufacture a strip from a specific alginate in combination with an active substance, that is released and delivered via the mucosa.
Nicoccino holds a license, from Uppsalagruppen Medical AB, to use the patent exclusively and without restrictions for products where nicotine is the active substance. The license is without royalty or any other cost, however, Nicoccino is responsible for a share of the patent’s maintenance fees.
The patent has been granted in 49 countries.
The patent expires in 2026 (2029 in the USA).